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Abstract
Background: A novel pattern in the indirect immunofluorescence antinuclear antibody assay on HEp-2 cells (IIF-HEp-2)
characterized by cytoplasmic rods and rings (RR) was reported in HCV patients, but stringent disease specificity studies and
longitudinal analysis are lacking. We investigated the clinical significance of anti-RR in an HCV cohort with up to a 12-month
treatment follow up.
Methodology/Results: 597 patients (342 HCV, 55 HCV/HIV, 200 non-HCV) were screened and titered for anti-RR. Serial
samples were available from 78 of 176 treated and 27 of 166 untreated patients. Anti-RR was detected in 14.1% of 342 HCV
patients, 9.1% of 55 HCV/HIV, 3.4% of 29 Hepatitis B, and none of 171 non-HCV (p,0.0001; HCV versus non-HCV). Anti-RR
was present in 38% of 108 patients receiving interferon-a/ribavirin, but none in 26 receiving either interferon-a or ribavirin,
or 166 untreated patients (p,0.0001). Other IIF-HEp-2 patterns were more frequently associated with interferon-a
treatment alone (52.2%) as compared to interferon-a/ribavirin (25%), ribavirin alone (33.3%), and no therapy (26.5%). Anti-
RR frequency was not associated with sex, age, ethnicity, HCV genotype or viral load. Anti-RR occurred only after initiation of
treatment, beginning as early as 1 month (6%), but by the sixth month .47% tested positive for anti-RR. The anti-RR titer
generally increased with sustained treatment and remained high in 53% of patients. After treatment, anti-RR titer was
negative in 41%. Non-responders to HCV therapy were 77% in anti-RR-positive versus 64% in anti-RR-negative patients.
Response to treatment was not associated with anti-RR titer or the dynamics of anti-RR reactivity during and after
treatment.
Conclusions: The exquisite association of anti-RR reactivity with combined interferon-a/ribavirin therapy in HCV patients
represents a unique model for drug-induced autoantibody generation in humans as demonstrated by the fact that a
significant fraction of patients who have anti-RR during therapy becomes anti-RR-negative after completion of therapy.
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Introduction
Autoantibodies with high avidity and in high concentration are
usually detected in sera of patients with systemic autoimmune
diseases, and indicate tolerance breakdown. The strict association
of some autoantibodies with certain diseases has granted them the
reputation of specific biomarkers [1,2,3,4]. The identification of a
novel autoantibody associated with a given disease may contribute
to the understanding of its pathophysiology and may enrich the
array of diagnostic tests for that disease [2]. The standard method
for autoantibody screening is the indirect immunofluorescence
assay on HEp-2 cells (IIF-HEp-2), historically known as the
antinuclear antibody ANA test. However, a positive IIF-HEp-2
test is also observed in some patients with infectious and malignant
diseases, as well as in up to 13% of healthy people [4,5,6].
A positive IIF-HEp-2 test has been reported in 7 to 50% of
patients with HCV [7,8,9,10,11]. The few studies reporting on the
immunofluorescence pattern of IIF-HEp-2 test in HCV patients
have emphasized the nuclear fine speckled pattern and cytoplas-
mic fibrillar pattern [8,9,10,12,13]. Most IIF-HEp-2 reactivity in
HCV patients is not associated with autoantibodies traditionally
related to specific autoimmune diseases. However, a small fraction
of HCV patients do present well characterized autoantibodies
conventionally associated with autoimmune hepatitis, such as anti-
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LKM and anti-smooth muscle antibodies [14,15,16]. Anti-LKM
antibody is classically associated with type 2 autoimmune hepatitis,
but it has been observed in up to 10% of HCV patients, mostly
males, and it appears to indicate mild liver histological and
biochemical alterations in these patients [15,17]. Anecdotal
reports suggest that interferon-a therapy may worsen inflamma-
tory liver activity and increase serum enzyme in LKM-reactive
HCV patients [17,18]. Anti-smooth muscle antibodies are directed
mostly to the polymerized form of actin and are traditionally
associated with type 1 autoimmune hepatitis, but they can also be
observed in a small fraction of HCV patients, usually at a lower
titer than in autoimmune hepatitis [16]. HCV patients presenting
anti-smooth muscle autoantibodies appear not to differ from those
without these autoantibodies concerning clinical profile and
response to treatment [15,19].
Recently a novel IIF-HEp-2 cytoplasmic pattern has been
reported in HCV patients [20,21,22,23,24,25]. It is characterized
by a variable number of 3–10 mm long rods and 2–5 mm diameter
rings spread throughout the cytoplasm. Accordingly, the novel IIF-
HEp-2 pattern has been designated the ‘‘rods and rings’’ (RR)
pattern. Interestingly, not all commercial HEp-2 slides are
appropriate for the observation of the RR pattern. In fact, in
many HEp-2 slides, the RR-positive serum samples yield a non-
specific cytoplasmic speckled pattern or no relevant staining at all.
This observation suggests that the target RR structures are evident
only under special conditions. Alternatively it may be that the
epitopes recognized by anti-RR antibodies are available only
under special conditions. The RR structures seem to bear no
relationship with the cytoskeleton, GW bodies, centrosomes,
primary cilia structures, or ‘‘actin rockets’’ [22]. On the other
hand, the RR structures resemble cytoplasmic structures previ-
ously reported in 1987 by Willingham, Richert, and Rutherford
[22,26]. These authors observed such structures in indirect
immunofluorescence with a monoclonal antibody obtained by
immunizing a Balb/c mouse with SR-Balb 3T3 cells. The putative
antigen was named ‘‘nematin’’ due to the vermiform appearance
of the stained structures and it could be detected in rat NRK and
SR-NRK cell lines, in mouse Swiss 3T3, Balb 3T3, and SR-Balb
cells, in human KB cells, and in bovine MDBK cells [26].
Unfortunately the monoclonal antibody, as well as the cell line, is
no longer available (Mark Willingham, M.D., Wake Forest School
of Medicine, personal communication).
At the moment it is not known why the IIF-HEp-2 RR pattern
occurs only in a fraction of HCV patients. The present work aims
to investigate how specific the anti-RR reactivity is to HCV and to
evaluate possible relationships between the occurrence of the anti-
RR reactivity and demographic, clinical, virological and thera-
peutic response characteristics of HCV patients.
Materials and Methods
We studied samples from 597 patients, including 342 HCV
patients, 55 HCV-HIV co-infected patients, and 200 miscella-
neous patients (see below). Serum samples (n = 514) from 342
HCV patients were sequentially selected from the serum bank
from the Gastroenterology Division at the Federal University of
Sa˜o Paulo (UNIFESP). All patients had a diagnosis of HCV
hepatitis confirmed by the presence of anti-HCV antibodies,
circulating HCV RNA, and biochemical and histological evidence
of hepatitis. In addition, samples from 55 patients with HCV and
HIV co-infection were analyzed. The control non-HCV group
comprised serum samples from 200 patients with various hepatic
and non-hepatic conditions not related to HCV, including
systemic autoimmune rheumatic diseases (51 systemic lupus
erythematosus, 36 systemic sclerosis, 8 polymyositis), multiple
sclerosis (n = 7), and different liver diseases (29 hepatitis B, 69
autoimmune hepatitis). Diagnostic classification of patients com-
plied with the internationally accepted classification criteria
[27,28,29,30,31,32,33,34,35]. All samples were obtained from
1998 to 2008 and were stored at 220uC. The informed consent
form was signed by patients currently followed at the institution.
For a small fraction of patients not available at the present time,
serum bank historical samples were used for assays regularly
ordered for their clinical conditions. The study has been approved
by the institution’s Ethics Committee.
Among the 342 HCV patients, 176 had been treated for HCV
and had available samples during and after treatment; 166 HCV
patients had not been treated. Serial samples (2 to 5) were
available from 105 patients, namely 27 untreated patients and 78
treated patients with samples before, during, and after treatment.
All co-infected patients had serial samples (2 to 4) before, during
and after the treatment. Clinical data were obtained from an
electronic data bank based on a structured protocol with detailed
parameters regarding clinical, biochemical, therapeutic response,
and virological aspects. The number of patients analyzed for
different parameters varied because not all parameters were
available for all patients. For the analysis of the occurrence of the
anti-RR reactivity as a function of treatment, only patients for
whom treatment had been indicated were included. HCV viral
load was determined by quantitative PCR (AmplicorH, Roche,
Basel, Switzerland) with sensitivity of 600 IU/mL and linearity up
to 850,000 IU/mL. Virologic response was determined in 125
patients who had consistent monitoring of HCV viral load within
the 6 months following completion of treatment. Patients with
consistently negative PCR for HCV up to 6 months after the end
of treatment were classified as having developed a sustained
virologic response. Patients who never had undetectable serum
HCV levels and those who had undetectable HCV at the end of
treatment, but presented detectable HCV within 6 months after
treatment suspension, were classified as non-responders.
All samples were processed for IIF with HEp-2 slides from
Euroimmun (Lu¨beck, Germany) and INOVA (San Diego, CA,
USA) at a screening dilution of 1/80 according to standard
indirect immunofluorescence protocol. Representative samples
were also tested in other HEp-2 slide brands: Hemagen (VirgoH,
Columbia, Maryland, USA), MBL Bion (Des Plaines, Illinois,
USA), and Immuno Concepts (Sacramento, CA, USA). In
addition, homemade slides were prepared by cultivating HEp-2
cells (ATCC #CCL-23; Virginia, USA) on round coverslips with
Dulbecco’s Modified Eagle Medium (DMEM) in 10% Fetal Calf
Serum (FCS) and 1% Gibco Antibiotic/Antimycotic reagent
(Penicillin G, Streptomycin, amphotericin) at 37uC and 5% CO2.
In some experiments, cells were treated with 2 mM ribavirin
(Farmanguinhos Laboratory, Rio de Janeiro, Brazil) and incubat-
ed for 24 h. Cells were fixed with methanol for 8 min and acetone
for 2 min at 220uC.
Briefly, samples were diluted at 1/80 in 0.15 M NaCl, 10 mM
phosphate buffered saline, pH 7.4 (PBS), and incubated with
HEp-2 cells for 30 min at room temperature in a moist chamber.
After washing twice in PBS for 10 min, cells were incubated with
fluorescein isothiocianate-labeled anti-human immunoglobulin
(IgG heavy and light chains) goat immunoglobulin for another
30 min period in the dark. After washing twice as before, slides
were assembled with buffered glycerol pH 9.5 and cover slips.
Autoantibody titer was determined by testing successive 2-fold
dilutions of the serum up to 1/10,240. Analysis was performed by
two independent expert observers (GDK & LEA) using an
Anti-RR Antibody Induced by Ribavirin/IFN-A in HCV
PLOS ONE | www.plosone.org 2 September 2012 | Volume 7 | Issue 9 | e45392
Olympus BX 50 microscope under 4006magnification. Images
were captured using a Carl Zeiss Axio-Imager M2 microscope.
Categorical variables, such as sex, age group, and IIF patterns,
were analyzed using the Chi-square test and the Fisher exact test
when appropriate. Quantitative and semi-quantitative parameters
with normal distribution were analyzed by ANOVA, and those
with non-Gaussian distribution were analyzed using the Kruskal-
Wallis test. All data were analyzed using SPSS for Windows 19.0.
p values less than 0.05 were considered significant.
Results
RR reactivity was readily recognized on Euroimmun and
INOVA HEp-2 slides but either non-specific cytoplasmic dots or
no relevant staining was observed with other commercial or
homemade HEp-2 slides (Figure 1). In contrast, typical RR
structures were readily apparent in HEp-2 cells treated with
ribavirin (Figure 1E). Anti-RR reactivity was detected in sera of 57
of the 597 patients studied (9.5%), including 56 of the 397 with
Hepatitis C (14.1%), 1 of 29 with Hepatitis B (3.4%), and none of
171 patients without any form of viral hepatitis. Thus, anti-RR
Figure 1. IIF-HEp-2 rods and rings pattern in different slide brands. Indirect immunofluorescence with a representative anti-RR-positive HCV
patient sample diluted 1/80. A, B, and C, slides from Euroimmun at61,000 magnification. (A) Ring conformation example; (B) Rod conformation
example; (C) Cell with both conformations, depicting the cytoplasmic localization underscored by DAPI staining of the nucleus. (D) Classical RR
pattern in INOVA slides, depicting a variable number of 3–10 mm long rods and 2–5 mm diameter rings in the cytoplasm. (E) Typical RR configuration
in home-made slides with HEp-2 cells treated with 2 mM ribavirin for 24 h. Non-specific cytoplasmic dots in non-treated home-made HEp-2 slides (F)
and in Bion HEp-2 slides (G), respectively. White bar: 20 mm.
doi:10.1371/journal.pone.0045392.g001
Table 1. Distribution of patients with HCV and other hepatic and non-hepatic diseases according to the presence of anti-RR and
other IIF-HEp-2 patterns.
IIF-HEp-2 patterns*
Disease groups NFS NHo NCS NQH Cen Cyt No RR Misc Overall IIF-HEp-2 reactivity
Hepatitis C (n = 342) 55 5 - 9 - 7 14 51** 26 145 (42%)
Hepatitis B (n = 29) 4 - - - - - - 1 - 5 (17%)
Autoimmune Hepatitis (n = 69) 21 3 1 16 1 1 2 - 14 49 (70%)
Systemic Lupus Erythematosus (n = 51) 25 16 4 1 - 1 5 - 2 46 (90%)
Systemic Sclerosis (n = 36) 9 4 5 3 8 - 6 - 6 32 (9%)
Polymyositis (n = 8) 5 - - 2 1 - 1 - - 8 (100%)
Multiple Sclerosis (n = 7) 1 - - - 1 - - - - 2 (29%)
HCV and HIV co-infection (n = 55) 7 - 1 - - 4 5 5 5 26 (47%)
*IIF-HEp-2 patterns were based on observation using INOVA and Euroimmun slides.
**Seven patients presented anti-RR reactivity associated with other pattern. We include these patients only in the anti-RR positive group.
NFS: Nuclear Fine Speckled; NHo: Nuclear Homogeneous; NCS: Nuclear Coarse Speckled; NQH: Nuclear Quasi Homogeneous; Cen: Centromere; Cyt: Cytoskeleton; No:
Nucleolar; RR: Rods and Rings; Misc: Miscellaneous patterns: Scl-70-like pattern, RNA polymerase I pattern, multiple nuclear dots, nuclear envelope, nuclear matrix, dense
fine speckled pattern.
doi:10.1371/journal.pone.0045392.t001
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reactivity was strongly associated with HCV (p,0.0001; Fisher’s
exact test between HCV and non-HCV controls). There was no
significant difference in anti-RR reactivity between 51 of the 342
patients (14.9%) with HCV infection alone and 5 of the 55 patients
(9.1%) with HCV/HIV co-infection (p = 0.301; Fisher’s exact test).
Except for the single patient with Hepatitis B, no sample from
patients with other hepatic diseases and systemic autoimmune
diseases presented anti-RR reactivity. In contrast, other IIF-HEp-
2 patterns were observed in variable proportions in all groups of
patients. The nuclear fine speckled pattern was the dominant
pattern in most patients, except for HCV patients in whom the RR
and nuclear fine speckled patterns displayed a similar frequency
(Table 1).
Among HCV patients, anti-RR reactivity was clearly associated
with treatment with ribavirin and interferon-a. Treatment with
interferon-a and/or ribavirin had been administered to 176 HCV
patients, while 166 HCV patients received no treatment. Anti-RR
reactivity was detected in 51 treated patients (29%), but in none of
the untreated patients (p,0.0001; Fisher’s exact test). In contrast,
other IIF-HEp-2 patterns were observed in 50 treated patients
(28.4%) and in 44 untreated patients (26.5%) (p = 0.598).
Information regarding the precise therapeutic regimen was
available for 134 patients: 108 were receiving interferon-a plus
ribavirin, 23 were receiving only interferon-a, and 3 patients were
receiving only ribavirin. Anti-RR reactivity was detected in 41
patients treated with interferon-a plus ribavirin (38%), but in none
of the patients treated with either one of the two drugs (p = 0.0001;
Fisher’s exact test, Figure 2). In contrast, other IIF-HEp-2 patterns
were more frequent in patients receiving only interferon-a (52.2%)
than in those treated with interferon-a plus ribavirin (25%) and
those treated only with ribavirin (33.3%) (p = 0.01) (Figure 2).
Accurate information on treatment was available for 21 patients
with HIV/HCV co-infection. Anti-RR reactivity was detected in 5
of the 20 patients treated with interferon-a plus ribavirin (20%),
but not in the single patient treated only with interferon-a.
The apparent association of anti-RR reactivity and therapy with
interferon-a plus ribavirin was further strengthened by the analysis
of serial samples of RR-positive patients before and after the
beginning of treatment. For this analysis, anti-RR reactivity was
compared in samples obtained before and each month after the
beginning of treatment, and also in samples obtained after
treatment had been discontinued. As observed in Figure 3A, all
pre-treatment samples were anti-RR negative, and an increasing
frequency of anti-RR was observed during the several months of
treatment. Even after discontinuation of therapy with interferon-a
plus ribavirin, some anti-RR reactivity was maintained when
evaluated up to one year later (Figure 3A). All time-point groups
after initiation of treatment showed higher frequency of anti-RR
reactivity compared to pre-treatment samples (p,0.001; Pearson
Chi-square test). In contrast, there was no difference in the
frequency of other IIF-HEp-2 patterns in samples obtained before
and after initiation of therapy with interferon-a plus ribavirin
(Figure 3B, p = 0.727). In addition, no anti-RR reactivity was
observed in the serial samples from 27 untreated patients. Treated
patients showed no statistical difference regarding the frequency of
anti-RR during the months on treatment (Figure 3A, p= 0.705).
There was consistent information on the profile of therapeutic
response for 125 patients, for whom no association was observed
between the appearance of anti-RR and therapeutic response. The
proportion of non-responders was equivalent (p = 0.271; Pearson
Chi-square test) in the 39 patients with anti-RR reactivity (77%),
40 patients with other IIF-HEp-2 patterns (60%), and 46 patients
with negative IIF-HEp-2 tests (67%, Figure 4A and 4B). In order
to examine possible influences of HCV genotype and viral load on
the pattern of response to treatment, the analysis was repeated
solely including patients infected with genotypes 1A, 1B, and 1C
(most prevalent HCV genotype in the region [36,37,38]), and with
baseline viral loads equal to or greater than 100,000 IU/mL at the
beginning of treatment. This analysis comprised 17 patients with
Figure 2. Antibodies to rods and rings are predominantly
observed in HCV patients undergoing treatment with interfer-
on-a plus ribavirin. Comparison of IIF-HEp-2 patterns in (A) Patients
with HCV and the control group (systemic lupus erythematosus,
systemic sclerosis, polymyositis, multiple sclerosis, hepatitis B, autoim-
mune hepatitis); (B) Treated and untreated HCV patients; and (C) HCV
patients treated with interferon-a plus ribavirin and those receiving
only interferon-a. Black bars: Anti-RR-reactive; gray-lined bars: other IIF-
HEp-2 patterns; gray solid bars: IIF-HEp-2-negative.
doi:10.1371/journal.pone.0045392.g002
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anti-RR and 20 patients presenting other IIF-HEp-2 patterns or
negative for the IIF-HEp-2 test. Fifteen of the anti-RR positive
patients (88%) and 17 of the anti-RR negative patients (85%) were
classified as non-responders (p = 1.000) (Figure 4C). Next the titer
of anti-RR antibodies was analyzed according to the profile of
therapeutic response. For this analysis, the highest titer in serial
samples for each patient was considered. The titer of anti-RR
reactivity for all anti-RR-positive patients (n = 57) varied from 1/
80 to $1/10240 with a median of 1/1280: 12 (21%) of the
samples had low titer (1/80 and 1/160), 5 (9%) had medium titer
(1/320), and 40 (70%) had high titer ($1/640). Among the 39
patients for whom information about therapeutic response was
available, anti-RR titer varied from 1/160 to $1/2,560. Patients
presenting sustained virologic response had titers of 1/160 to 1/
2,560, with a median of 1/1,280. Non-responders had titers
varying from 1/80 to 1/2,560, with a median of 1/1,280. There
were 26 patients with high titer ($1/640) and 11 patients with low
titer anti-RR reactivity (#1/160). Two patients had intermediate
titers of 1/320. Among patients with high titer anti-RR reactivity,
19 (73%) were non-responders and 7 (27%) presented sustained
virologic response. Among those with low titer anti-RR reactivity,
9 (82%) were non-responders and 2 (18%) presented sustained
virologic response (p = 0.694; Fisher’s exact test).
For 17 anti-RR-positive patients receiving the first round of
treatment, there were at least four sequential samples, including
the pre-treatment sample. All these samples were blind and
simultaneously processed for the determination of anti-RR titer.
For all patients, the baseline pre-treatment sample was negative
and anti-RR reactivity started at low titer and increased as the
treatment progressed (Figure 5). The temporal appearance of anti-
RR at the beginning, during, and after therapy was further
analyzed. There was an overall trend for increase in anti-RR titer
during the therapy (Figure 5B and C), but there was considerable
heterogeneity in the tempo and steadiness of anti-RR titer among
different patients. There was also heterogeneity regarding the
interval from the beginning of therapy and the first positive result
for anti-RR reactivity. Only two patients (12%) showed anti-RR
reactivity before 6 months of treatment. In 10 of the 17 patients
(59%), anti-RR reactivity first appeared before or at the sixth
month of treatment (early appearance), and 7 patients (41%)
showed anti-RR reactivity at or after the 9th month of therapy (late
appearance; Figure 5A and B). Sustained virologic response was
observed in 3 of the patients with early anti-RR appearance (30%)
and in 3 of those with late anti-RR appearance (43%) (p = 0.643;
Fisher’s exact test). In the six months after treatment discontin-
uation, patients showed heterogeneous anti-RR behavior: nine
patients kept or increased their previous titer, and eight patients
became negative or dropped in titer to 1/80 (Figure 5B and C). No
relationship was apparent between anti-RR titer after discontin-
uation of treatment and the profile of therapeutic response, since
an unsatisfactory therapeutic response was observed in 7 (77%) of
those patients who maintained high titer anti-RR reactivity and in
5 (62.5%) of those who experienced an accentuated drop in anti-
RR reactivity.
Next we investigated the possible influence of demographic
variables, HCV genotype, and HCV viral load on the occurrence
of anti-RR reactivity in patients treated with interferon-a plus
ribavirin. As depicted in Table 2, patients divided according to
IIF-HEp-2 patterns (negative, RR, and other IIF-HEp-2 patterns)
did not differ according to age (p = 0.199; ANOVA), sex
(p = 0.762; Pearson Chi-square test), or ethnic group (p = 0.417;
Pearson Chi-square test). There was also no difference in the
average duration of Hepatitis C diagnosis (p = 0.515; ANOVA).
The predominant HCV genotypes were 1A (47%) and 1B (38%),
and there was no difference in genotype distribution according to
the IIF-HEp-2 patterns (p = 0.679; Pearson Chi-square test). As
depicted in Table 2, HCV viral load was similar in anti-RR-
reactive patients (361,222664,842), IIF-HEp-2-negative patients
(348,492658,816), and patients with other IIF-HEp-2 patterns
(390,194666,071; p = 0.776; Kruskal-Wallis test).
Discussion
Anti-RR reactivity has been reported in the last few years as a
peculiar IIF-HEp-2 pattern observed with samples from HCV
patients [20]. Preliminary work has indicated that this novel IIF-
HEp-2 pattern occurs predominantly in HCV patients undergoing
therapy with interferon-a [21,22] It has also been demonstrated
that the RR pattern is observed solely when using certain HEp-2
slide brands. This observation implies that the RR structures are
not readily available under regular circumstances and that they
must be induced by particular cultivation and fixation conditions.
In fact that was observed with the in vitro treatment of HEp-2 cells
with ribavirin. Another possibility could be that the recognized
epitopes may not be naturally found under physiologic conditions.
However, the observation that anti-RR samples elicit an array of
cytoplasmic patterns – ranging from non-specific dots to fine
speckles – in other HEp-2 slide brands and in homemade HEp-2
slides suggests that the recognized epitopes are indeed naturally
Figure 3. Anti-RR reactivity occurs at varying intervals after the beginning of treatment. Samples from HCV patients were obtained at
baseline, at successive months after beginning of treatment with interferon-a plus ribavirin, and 6–12 months after treatment discontinuation. (A)
Anti-RR was absent in samples obtained at the beginning of treatment and there was a clear trend for increasing frequency in samples obtained
along several time points during and after treatment; the frequency rate differed between the pre-treatment bleed and other time points, but not
among the several bleeds after the beginning of treatment (p = 0.705). (B) The frequency of other IIF-HEp-2 patterns was equivalent in samples
obtained before the beginning of treatment and in those obtained along and after the treatment (p = 0.727).
doi:10.1371/journal.pone.0045392.g003
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available in less characteristic arrangements as compared to the
RR structures.
The present study focused solely on the clinical aspects of this
particular immune response in an attempt to understand what
factors are involved in its occurrence. We were able to confirm
that antibodies associated with the RR pattern are strongly
associated with Hepatitis C. In addition, we could demonstrate
that the occurrence of anti-RR reactivity is promoted by the
combined therapy with interferon-a plus ribavirin and that its
frequency increases with the length of treatment, but it was not
observed in patients treated with either one of these two drugs
alone. No relationship could be recognized between anti-RR
reactivity and demographic parameters, duration of HCV
diagnosis, pattern of response to treatment, HCV genotype, or
HCV viral load. In addition, the existence of co-infection with
HIV did not affect the occurrence of anti-RR reactivity in HCV
patients and its relationship with combined interferon-a plus
ribavirin therapy.
The association of anti-RR reactivity and combined therapy
with interferon-a plus ribavirin is an interesting finding. It is well
known that interferon-a is able to stimulate innate immunity and
has a general adjuvant effect on the immune system. Interferon-a
is a type 1 interferon produced by B and T lymphocytes, NK cells,
monocytes, and virus-infected cells. After binding to surface
receptors, it activates Janus-activated kinase-1 (Jak1) and tyrosine
kinase 2 (Tyk2) that phosphorylate the signal transducers and
activators of transcription proteins (STAT1 and STAT2) [39,40].
Activated STAT1 and STAT2 reach the nucleus where they bind
to the interferon regulator factor 9 (IRF-9) to form a complex that
will promote the transcription of a series of interferon-stimulated
genes (ISG). The products of ISG block the synthesis of viral
proteins by inhibiting the Eukaryotic Initiation Factor eIF2 and
therefore contribute to the establishment of an antiviral intracel-
lular environment [41,42,43,44]. In addition, type 1 interferons
act indirectly against the virus by means of stimulating the immune
response. Generation of antibodies and autoantibodies seems to be
boosted by persistently increased concentration of type 1
interferon. In fact, systemic lupus erythematosus, possibly the
disease with the highest occurrence of autoantibodies, has been
demonstrated to exhibit high levels of circulating type 1 interferon
and increased expression of ISG [45,46]. In the present study we
could confirm the autoantibody-inducing ability of interferon-a by
the observation that 52% of HCV patients receiving just
interferon-a, but only 26.2% of untreated patients, presented a
positive IIF-HEp-2 test. Interestingly, none of these HCV patients
exclusively receiving interferon-a developed antibodies associated
with the IIF-HEp-2 RR pattern. This is in accordance with the
observation that anti-RR reactivity was also not observed in
patients with systemic lupus erythematosus.
The fact that isolated interferon-a therapy was not associated
with anti-RR reactivity appeared to suggest that ribavirin would
be required for this peculiar type of antibody response. Ribavirin is
a synthetic guanosine analog with direct action against RNA and
DNA viruses, possibly through inhibition of virus-dependent
polymerases. Similarly to guanosine, ribavirin is phosphorylated
within the cell into monophosphate (RMP), diphosphate (RDP),
and triphosphate (RTP) ribavirin. The interaction of RTP with
cellular and viral enzymatic machineries has a host of effects,
including the inhibition of inosine monophosphate dehydrogenase
with depletion of guanosine triphosphate (GTP) necessary for viral
RNA synthesis [47], direct inhibition of HCV RNA polymerase
NS5B RdRp [48,49], and induction of a high rate of viral RNA
mutagenesis resulting in a decline in the number of viable viral
copies [50,51]. However, these effects vary depending on the
particular virus and RTP has been shown to be a weak inhibitor
for viral RNA polymerases related to HCV [52]. Ribavirin also
enhances hepatocyte gene response to peginterferon [53].
Accordingly, ribavirin on its own is effective for only a minority
of HCV patients, but it is a valuable adjuvant in the therapy with
interferon-a [54].
Curiously, the few patients receiving only ribavirin did not
present anti-RR reactivity. Although one cannot rule out that
ribavirin alone can trigger anti-RR, it appears that the occurrence
of anti-RR reactivity is strongly favored by the combined effects of
interferon-a and ribavirin. It is possible that interferon-a is
required to stimulate the occurrence of anti-RR reactivity
apparently driven by ribavirin. Recent reports suggested that
possible targets of anti-RR reactivity include CTP synthase and
Figure 4. Anti-RR is not related to sustained virologic response.
The frequency of samples with RR IIF-HEp-2 pattern, other patterns and
those with a negative test was equivalent in patients exhibiting
sustained virologic response and those classified as non-responders. (A
and B) HCV patients in general; (C) HCV patients with genotype 1 and
viral load above 100,000 IU/mL. Gray bars: sustained virologic response;
black bars: non-responder patients.
doi:10.1371/journal.pone.0045392.g004
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Inosine-59-monophosphate dehydrogenase-2 (IMPDH2), an en-
zyme involved in the generation of GTP and inhibited by ribavirin
[23,24,25]. The observation that HEp-2 cells treated in vitro with
ribavirin were an adequate substrate to yield typical RR structures
reinforces the idea that ribavirin is involved in the particular
spatial rearrangement of these putative autoantigens and this may
contribute to the generation of autoantibodies against these
enzymes. In this sense it is particularly exciting that three recent
independent studies have demonstrated that CTP synthase may
polymerize under special conditions and present as filamentous
cytoplasmic structures reminiscent of the rods of RR structures
[55,56,57,58].
Despite the evidence implying interferon-a and ribavirin in the
induction of anti-RR reactivity, it is important to emphasize that
one Hepatitis B patient treated with lamuvidine also presented the
characteristic anti-RR reactivity with titer .1/1280. Unfortu-
nately the baseline serum sample for this patient was not available.
However, the titer of anti-RR antibodies after the patient’s first
month of treatment was at 1/80 and subsequently increased along
with treatment up to 1/1,280 at the twelfth month. This
observation may suggest that lamuvidine may also contribute to
exposure of RR-related immunogenic epitopes and that liver
inflammation per se may also exert adjuvant effects toward the
occurrence of this particular antibody response.
Figure 5. Anti-RR first appearance and titer behavior during and after treatment discontinuation. (A) Time for first appearance of anti-RR
reactivity. For those 17 patients included in this analysis, 8 (47%) presented anti-RR reactivity at the sixth month of treatment and two produced their
first anti-RR sample after treatment discontinuation (in red dashed lines in panel B). (B) Nine patients kept or increased the titer of anti-RR after
treatment discontinuation. Titer showed a trend for increasing along anti-HCV treatment and after treatment discontinuation. Double black
line = overall trend; red dashed line = anti-RR titer increased after treatment discontinuation (n = 5); blue dots line = anti-RR titer was stable after
treatment discontinuation (n = 4). (C) In eight patients, anti-RR reactivity became negative (color dashed and dots lines, n = 7) or dropped down to 1/
80 (red dashed line, n = 1) after treatment discontinuation. Double black line = overall trend. 0 = negative. Dilution was from 1/80 into 1/2560 for this
analysis.
doi:10.1371/journal.pone.0045392.g005
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Conclusions
In conclusion, the present study independently confirmed the
strict association of the IIF-HEp-2 RR pattern with HCV and
extended this association to HCV/HIV co-infection. In addition
we were able to narrow down the trigger for anti-RR reactivity to
the combined interferon-a plus ribavirin therapy. In contrast, no
association was detected with demographic parameters, duration
of diagnosis, response to treatment, HCV genotype, or HCV viral
load. Despite the clear association of anti-RR reactivity and
combined interferon-a plus ribavirin therapy, it is striking that the
majority (62%) of patients under this therapy showed no anti-RR
reactivity. This observation indicates that other factors must play a
role in determining the occurrence of this peculiar antibody
response. Future studies should address potential candidate
factors, such as the MHC genotype, the severity and extent of
liver inflammatory reaction, and genetic polymorphism related to
enzymes involved in the processing of ribavirin or to enzymes
targeted by ribavirin.
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